Consensus ORIC Pharmaceuticals, Inc.

Equities

ORIC

US68622P1093

Real-time Estimate Cboe BZX Other stock markets 11:13:48 30/04/2024 pm IST			5-day change	1st Jan Change
9.005 ^USD	+9.42%		+1.82%	-2.93%

15/04	ORIC Pharmaceuticals Doses First Patients in Expansion Groups in Phase 1b Trial of ORIC-114 to Treat Lung Cancer	MT
15/04	ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC	CI

Evolution of the average Target Price on ORIC Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

17a4de88c27373d723b428d.9oiW5heagtCFLhOQzVZE0Vz-GDklMgvdrtovZoQFFK8.l_7Zgyasw7zsTSTxuDcooS6hW3RNSmbt5L0XDLRKJe26zqC1f_6wgu9heA~6ff147e74cf7910595228db113aab8f5

Analyst Recommendations on ORIC Pharmaceuticals, Inc.

JPMorgan Trims ORIC Pharmaceuticals' Price Target to $18 From $19, Maintains Overweight Rating	27/03	MT
HC Wainwright Adjusts ORIC Pharmaceuticals' Price Target to $21 From $15, Keeps Buy Rating	21/03	MT
Baird Cuts Price Target on ORIC Pharmaceuticals to $25 From $27, Maintains Outperform Rating	12/03	MT
Wedbush Adjusts Oric Pharmaceuticals' Price Target to $20 From $12, Maintains Outperform Rating	01/03	MT
Cantor Fitzgerald Initiates ORIC Pharmaceuticals at Overweight Rating	26/02	MT
HC Wainwright Trims Price Target on ORIC Pharmaceuticals to $15 From $16, Keeps Buy Rating	13/12	MT
Wedbush Lowers ORIC Pharmaceuticals' PT to $12 From $14, Pushes Out Launch Assumption for ORIC-533; Keeps Outperform Rating	12/12	MT
HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $16 From $13, Maintains Buy Rating	26/23/26	MT
JPMorgan Adjusts ORIC Pharmaceuticals' Price Target to $17 From $14, Maintains Overweight Rating	24/23/24	MT
Citigroup Adjusts ORIC Pharmaceuticals' Price Target to $15 From $13, Maintains Buy Rating	23/23/23	MT
Wedbush Starts ORIC Pharmaceuticals at Outperform With $14 PT, Says Expanding Pipeline Provides Future Potential Growth Opportunities	22/23/22	MT
Baird Adjusts Price Target on ORIC Pharmaceuticals to $27 From $15, Keeps Outperform Rating	16/23/16	MT
HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $13 From $14, Keeps Buy Rating	15/23/15	MT
HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $14 From $16, Keeps Buy Rating	10/23/10	MT
Citigroup Adjusts Price Target on ORIC Pharmaceuticals to $8 From $9, Maintains Buy Rating	05/23/05	MT
HC Wainwright Upgrades ORIC Pharmaceuticals to Buy From Neutral, Price Target is $16	23/23/23	MT
Guggenheim Upgrades ORIC Pharmaceuticals to Buy From Neutral, Price Target is $15	21/23/21	MT
JPMorgan Adjusts Price Target on ORIC Pharmaceuticals to $15 From $16, Maintains Overweight Rating	21/23/21	MT
Oppenheimer Upgrades ORIC Pharmaceuticals to Outperform From Perform, $14 Price Target	16/23/16	MT
Citigroup Adjusts ORIC Pharmaceuticals' Price Target to $9 from $10, Keeps Buy Rating	20/22/20	MT
Citigroup Upgrades ORIC Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $10 From $7	04/22/04	MT
HC Wainwright Downgrades ORIC Pharmaceuticals to Neutral From Buy	25/22/25	MT
Oppenheimer Downgrades ORIC Pharmaceuticals to Perform From Outperform Following Discontinuation of ORIC-101, Removes $52 Price Target	22/22/22	MT
Citigroup Downgrades ORIC Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $7 From $22	22/22/22	MT
Guggenheim Downgrades ORIC Pharmaceuticals to Neutral From Buy	22/22/22	MT